A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

Summary

This study will evaluate the long-term safety and efficacy of AXS-05 in subjects with Alzheimer's disease (AD) agitation.

Timeline

Start

2021-06-17

Primary completion

2024-12-03

Completion

2024-12-21

Outcome

Met primary endpoint

release “The ACCORD-2 Phase 3 trial achieved the primary endpoint with AXS-05 statistically significantly delaying the time to relapse of agitation” gcs-web.com ↗

Drugs

Indications